Bortezomib-induced posterior reversible encephalopathy syndrome: a case report

Abstract

Posterior reversible encephalopathy syndrome (PRES) is an uncommon neurological syndrome due to autoregulation breakthrough with subsequent predominantly vasogenic oedemain associated with several clinical conditions. It is being increasingly reported in antineoplastic-treated patients. Here we report the case of a 72-year-old man who developed PRES during the second cycle of bortezomib treatment for multiple myeloma. Unlike usual PRES cases, only moderate hypertension was present at symptom onset, supporting the hypothesis that alterations of the vascular endothelium and blood-brain-barrier are the principal pathophysiological mechanisms involved in bortezomib-induced PRES. Prompt recognition of this potentially serious neurological adverse event is paramount to prevent mortality and long-term sequelae.

Keywords

Bortezomib / chemotherapy / multiple myeloma / posterior reversible encephalopathy syndrome

References

[1] Fugate JE.Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions..Lancet Neurol2015;14:914-25

[2] Terwiel E,Lueck C.Reversible posterior encephalopathy syndrome associated with bortezomib..Intern Med J2010;40:69-71

[3] Kelly K,Murphy P.Bortezomib-induced reversible posterior leucoencephalopathy syndrome..Br J Haematol2008;141:566

[4] Kager LM,Kloppenborg RP,Van den Born BJ.Reversible posterior leucoencephalopathy syndrome associated with bortezomib in a patient with relapsed multiple myeloma..BMJ Case Rep2009;2009:bcr06.2009.1926

[5] Oshikawa G,Doki N,Kakihana K,Endo I,Ohashi K.Bortezomib-induced posterior reversible encephalopathy syndrome in a patient with newly diagnosed multiple myeloma..Intern Med2013;52:111-4

[6] Nixon NA.Posterior reversible encephalopathy syndrome resulting from repeat bortezomib usage..BMJ Case Rep2014;2014:bcr2014204592

[7] Ho CH,Tu MC.Bortezomib-induced posterior reversible encephalopathy syndrome: clinical and imaging features..Intern Med2014;53:1853-7

[8] Hsiao SC,Chang H.Recurrent capillary leak syndrome following bortezomib therapy in a patient with relapsed myeloma..Ann Pharmacother2010;44:587-9

[9] Tlemsani C,Boudou-Rouquette P,Maley K,Coriat R.Posterior reversible encephalopathy syndrome induced by anti-VEGF agents..Target Oncol2011;6:253-8

[10] Najera JE,Bashir Q,Champlin RE,Giralt S,Popat UR.Neurotoxicity after high-dose melphalan..J Clin Oncol2012;30:suppl 15abstr6546